Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A new study suggests that medications like Ozempic could help reduce the risk of overdose and alcohol intoxication in people ...

Viet Le, PA-C, Intermountain Health, gives insights into the benefits cardio-renal-metabolic care models provide for patients ...

A new study reveals that glucagon-like peptide-1 receptor agonists (GLP-1), which include weight loss and diabetes meds ...

New research shows that Ozempic and similar drugs reduce opioid overdoses by 40% and alcohol intoxication by 50% in people ...

Ozempic and other semaglutide medications for weight loss have been linked to hair loss on social media. Experts share who is ...

Only 15% of those who start a glucagon-like peptide 1 (GLP-1) for weight loss are still taking it two years according to ...

The use of GLP-1 RAs is associated with the risk for retained gastric contents and inadequate bowel preparation during endoscopic procedures.

The FDA has already made more than a dozen cancer drug approval decisions this year and more expected in the next several ...

Patients aged 10 to 17 years who are prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are more likely to have comorbid type 2 diabetes, high body mass index, and a previous metformin ...

A large study of veterans with type 2 diabetes finds better short-term kidney outcomes with use of SGLT2 inhibitors vs GLP-1 receptor agonists.

GLP-1 receptor agonists and similar drugs may protect people with opioid or alcohol use disorder from opioid overdose and ...